The merger between Microcide Pharmaceuticals Inc. and privately held Althexis Co. Inc. does not bring old-timer MCDE any closer to a marketed product, but it does provide Althexis Chairman and CEO Mark Skaletsky with some of the programs he needs to integrate downstream.

MCDE, founded in 1992, does infectious diseases-related target discovery using its VALID Microbial Genomics technology. It has a Phase I development program with partner R.W. Johnson Pharmaceutical Research Institute (Raritan, N.J.) for